This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include Live Oak Bancshares, Marriott International, Cardinal Health, Fabrinet and Wingstop
by Zacks Equity Research
Live Oak Bancshares, Marriott International, Cardinal Health, Fabrinet and Wingstop are part of the Zacks Screen of the Week article.
5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016
by Sweta Killa
The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.
AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.
5 Low-Leverage Stocks to Buy Amid Mixed Investor Sentiments
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy LOB, MAR, CAH, FN and WING.
5 Impressive MedTech Industry Growth Stocks to Buy for 2024
by Moumi Mondal
Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.
Wingstop and Marriott Vacations Worldwide have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Wingstop and Marriott Vacations Worldwide are part of the Zacks Bull and Bear of the Day article.
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
by Zacks Equity Research
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
3 Top Dividend Aristocrats to Buy Ahead of 2024
by Tirthankar Chakraborty
Some of the dividend aristocrats, such as Cardinal Health (CAH), Atmos Energy (ATO) and NextEra Energy (NEE), have a better-quality business and strong underlying fundamentals.
Should Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OMFL
5 Broker-Favorite Stocks to Keep an Eye on as 2024 Approaches
by Maharathi Basu
We believe that stocks like American Airlines (AAL), ABM Industries (ABM), Cardinal Health (CAH), Cleveland-Cliffs (CLF) and Cencora (COR) should be on an investor's watchlist.
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal (CAH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
McKesson (MCK) Announces Availability of FDA-Cleared Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.
Zacks.com featured highlights Cboe Global Markets, Cardinal Health, Assurant, Installed Building Products and FedEx
by Zacks Equity Research
Cboe Global Markets, Cardinal Health, Assurant, Installed Building Products and FedEx have been highlighted in this Screen of The Week article.
Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.
5 Dividend Stocks Having Strong Growth Potential
by Sweta Killa
Cboe Global (CBOE), Cardinal Health (CAH), Assurant (AIZ), Installed Building Products (IBP) and FedEx (FDX) have a strong dividend growth potential.
5 Broker-Friendly Stocks to Keep an Eye on Amid Volatility
by Maharathi Basu
We believe that stocks like Brinker International (EAT), Cardinal Health (CAH), The Andersons (ANDE), Avnet (AVT) and Group 1 Automotive (GPI) should be on an investor's watchlist.
This Combination of 3 Stocks Provides Monthly Income
by Derek Lewis
Investors who select stocks in a structured manner can create a portfolio that pays them monthly. Who doesn't love payday?
3 Reasons to Retain Inspire Medical (INSP) Stock for Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome
by Zacks Equity Research
Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.